Canadian Cardiovascular Society


The CCS National Active Surveillance Study of Myocarditis and/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) 
Members of the MYCOVACC Study Team, from left to right: Dr. Peter Liu, Dr. Sean Virani, Dr. Michael McDonald, Meredith Wright, Dr. Tahir Kafil, Susanna Ogunnaike-Cooke, Carolyn Pullen, Dr. Nat Hawkins at the 2022 Canadian Cardiovascular Congress in Ottawa.

Press Releases

Join the MYCOVACC study

The CCS is actively recruiting cardiac care centres, cardiology clinics and cardiologists from across the country to contribute to this multi-centre study. Study participants will be assessed at three months and 12 months after diagnosis and then annually for up to three years by a participating specialist. They will also be invited to complete quality of life, mental health, physical activity, and health outcomes questionnaires.

Contact the MYCOVACC study team:


Learn More

Read (NEW):
McDonald, M.A., Kafil, T.S, Khoury, M., Luk, A.C., Wright, M.K, & Hawkins, N. M. (2024). Myocarditis and pericarditis following mRNA COVID-19 vaccination: 2024 status and management update. Canadian Journal of Cardiology

Watch (NEW):
Myocarditis and Pericarditis after mRNA COVID-19 Vaccination: Status and Management Update (2024)

This CCS continuing professional development webinar provides an update on post-vaccine myocarditis and pericarditis from public health, cardiology, and family medicine perspectives.

Vaccine-Associated Myocarditis: Insights from the CCS MYCOVACC Surveillance Study (2023)

This Vascular 2023 session updates the Canadian cardiovascular community on MYCOVACC.

Patient and Healthcare Provider Resources (NEW)

Information for Patients:

Management Algorithm for Health Care Providers:

The updated post-vaccine myocarditis and pericarditis resources were developed in collaboration with the Centre for Evidence-Based Implementation, McMaster University. They are informed by Myocarditis and Pericarditis following mRNA COVID-19 Vaccination: 2024 Status and Management Update in the Canadian Journal of Cardiology.  The resources are available in English and French.


The MYCOVACC governance structure aims to facilitate the participation and collaboration of CCS members, CCS Affiliate societies, investigators, and patients in study activities.

Steering Committee

The MYCOVACC Steering Committee is chaired by Dr. Nathaniel Hawkins. It includes CCS members as well as representatives from key partner networks and the Public Health Agency of Canada.

Read member biographies.

The views expressed herein do not necessarily represent the views of the Public Health Agency of Canada.

Back to top